Prescription medication · RANK Ligand Inhibitor
denosumab
Also sold as Prolia, Xgeva. Stoboclo treats osteoporosis in women after menopause who are at high risk for fractures.
Data updated 2026-05-15
- 196,342
- FDA reportsHeavily reported
- $1723.69
- Brand price (NADAC)
denosumab (Prolia) is a prescription RANK Ligand Inhibitor. Stoboclo treats osteoporosis in women after menopause who are at high risk for fractures.
Stoboclo is a medicine that helps to treat osteoporosis and increase bone mass. It works by blocking a protein that breaks down bone.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$1723.69/unit
Generic Available
No
Pricing data from NADAC (CMS), effective November 20, 2024. Compare all drug costs →
What it does
Stoboclo treats osteoporosis in women after menopause who are at high risk for fractures.
Common side effects
Back pain, Pain in your arms or legs, Muscle and bone pain
Key warnings
Stoboclo can cause very low calcium levels in people with serious kidney disease, especially those on dialysis.
The sections below are summarized in plain English from denosumab's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Stoboclo blocks a protein called RANKL. RANKL tells your body to break down bone. By blocking RANKL, Stoboclo slows down bone loss and helps to increase bone mass.
Side Effects (from patient reports)
Based on 196,342 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for denosumab, by number of reports
- Death
Death
19,930 reports
- Arthralgia
Arthralgia
8,682 reports
- Osteonecrosis Of Jaw
Osteonecrosis Of Jaw
8,425 reports
- Fatigue 7,481
Fatigue
7,481 reports
- Pain In Extremity 6,893
Pain In Extremity
6,893 reports
- Pain 6,774
Pain
6,774 reports
- Back Pain 6,757
Back Pain
6,757 reports
- Nausea 5,301
Nausea
5,301 reports
- Diarrhoea 5,093
Diarrhoea
5,093 reports
- Fall 4,973
Fall
4,973 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for denosumab each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where denosumab sits
denosumab has more FDA adverse-event reports than 94% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is denosumab; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 196,342 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2008–2025.
Total Reports
196,342
Reports Mentioning Death
25,105
12.8% of reports — not proof of cause
Hospitalization Reports
30,164
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 2 | DEATH | 19,930 |
| 3 | ARTHRALGIA | 8,682 |
| 4 | OSTEONECROSIS OF JAW | 8,425 |
| 5 | FATIGUE | 7,481 |
| 6 | PAIN IN EXTREMITY | 6,893 |
| 7 | PAIN | 6,774 |
| 8 | BACK PAIN | 6,757 |
| 9 | NAUSEA | 5,301 |
| 10 | DIARRHOEA | 5,093 |
| 11 | FALL | 4,973 |
| 12 | RASH | 4,215 |
| 13 | MYALGIA | 4,163 |
| 14 | BONE PAIN | 3,978 |
| 15 | ASTHENIA | 3,959 |
| 16 | PRODUCT STORAGE ERROR | 3,667 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Stoboclo can cause very low calcium levels in people with serious kidney disease, especially those on dialysis. This can lead to hospitalization, life-threatening problems, and even death. If you have kidney problems, your doctor should check you for mineral and bone disorders before you start Stoboclo. You should be watched closely by a doctor who knows how to treat these problems.
Common Questions
What if I have kidney problems?
Can I take Stoboclo if I'm pregnant?
How often do I get the Stoboclo shot?
What else should I take with Stoboclo?
What are the most common side effects?
What if I have low calcium levels?
Can Stoboclo cause problems with my jaw?
What happens if I stop taking Stoboclo?
Can I give myself the Stoboclo shot?
What should I do if I have signs of an infection?
What are the common side effects of denosumab?
What drug class is denosumab?
What pregnancy or breastfeeding source fields are listed for denosumab?
Related Medications in RANK Ligand Inhibitor
Other drugs grouped near denosumab - same-class peers and common alternatives.
abaloparatide
Tymlos
Tymlos is a medicine to treat osteoporosis.
Compare with denosumab →
alendronate
Fosamax
Binosto is a medicine that helps make your bones stronger.
Compare with denosumab →
calcitonin
Miacalcin, Fortical
Calcitonin is a medicine that helps manage calcium levels in your body.
Compare with denosumab →
ibandronate
Boniva
Ibandronate (Boniva) is a medicine that helps treat and prevent bone loss in women after menopause.
Compare with denosumab →
risedronate
Actonel
Risedronate sodium delayed-release tablets help treat osteoporosis after menopause.
Compare with denosumab →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for denosumab: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 196,342.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 12.79%.
- cimetidine Δ 0.01 pts · 9,140 reports · H2 Receptor Antagonist 12.78%death share
- warfarin Δ 0.01 pts · 124,873 reports · Vitamin K Antagonist (Anticoagulant) 12.77%death share
- hydrocortisone Δ 0.04 pts · 84,725 reports · Corticosteroid 12.83%death share
- acyclovir Δ 0.08 pts · 109,698 reports · Antiviral (Nucleoside Analog) 12.71%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on denosumab
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for denosumab
The FDA label for denosumab (sold under brand names such as Prolia, Xgeva) classifies it as a prescription-only medication in the RANK Ligand Inhibitor class. Stoboclo treats osteoporosis in women after menopause who are at high risk for fractures. Official labeling lists 7 commonly reported side effects, including Back pain, Pain in your arms or legs, Muscle and bone pain.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 196,342 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: October 22, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages